目的 观察吉西他滨对非小细胞肺癌患者化疗疗效,分析化疗疗效与病理组织核糖核苷酸还原酶M1(RRM1)和核苷酸切除修复交叉互补基因1(ERCC1)表达的相关性.方法 收集96例非小细胞肺癌患者的临床资料,所有患者均经吉西他滨+顺铂化疗,用免疫组化法检测化疗前患者病理组织RRM1、ERCC1的表达情况,化疗3周后分析病理组织RRM1、ERCC1表达情况与患者临床特征,化疗疗效相关性.结果 化疗后,RRM1阳性表达率为60.42％;ERCC1阳性表达率为43.75％;非小细胞肺癌患者病理组织RRM1及ERCC1阳性表达与患者性别及吸烟情况有显著相关性(P＜0.05或P＜0.01),而与患者年龄、临床分期无显著相关性(均P ＞0.05);病理组织RRM1/ERCC1+/+,-/-,+/-或-/+非小细胞肺癌患者有效率分别为17.95％,74.29％及59.09％,病理组织RRM1/ERCC1-/-非小细胞肺癌患者有效率显著高于+/+,+/-或-/+者(P＜0.05或P＜0.01);且RRM1/ERCC1+/-或/+者有效率显著高于RRM1/ERCC1+/+者(均P＜0.05).经Spearman相关性分析显示,非小细胞肺癌患者病理组织RRM1、ERCC1阴性表达均与患者化疗疗效显著正相关(r=0.248,0.306,均P＜0.05).结论 吉西他滨化疗对非小细胞肺癌患者具有一定的临床疗效,其与患者病理组织RRM1、ERCC1蛋白阴性表达具有显著正相关性,两者可作为非小细胞肺癌化疗疗效的评估指标.“,”Objective To explore the chemotherapeutic effect of gemcitabine for non-small cell lung cancer patients and analyzed the correlation of chemotherapeutic effect with ribonucleotide reductase M1 (RRM1),excision repair cross-complementing 1 (ERCC1) expression in pathological tissue.Methods The clinical data of 96 non-small cell lung cancer patients were selected.All patients were treated with gemcitabine + cisplatin chemotherapy,and the RRM1,ERCC1 expression in pathological tissue were detected by immunohistochemical method at 3 weeks after chemotherapy,the correlation of clinical features with chemotherapeutic effect were analyzed.Results The positive expression rates of RRM1 and ERCC1 were 60.42％,43.75％.The positive expression of non-small cell lung cancer patients pathological tissue RRM1,ERCC1 had significant correlation with the gender and smoking status (P ＜0.05 or P ＜0.01),while had no correlation with the age and clinical stages (all P ＞0.05).The effective rates of patients with pathological tissue RRM1/ERCC1 +/+,-/-,+/-or-/+ were 17.95％,74.29％ and 59.09％,and the effective rates of patients with pathological tissue RRM1/ERCC1-/-were higher than +/ +,+/-or-/+ (P ＜0.05 or P ＜ 0.01),and the effective rates of patients with pathological tissue RRM1/ERCC1 + /-or-/ + were higher than RRM1/ERCC1 + / + (all P ＜ 0.05).Spearman correlation analysis showed that,the negative expression of non-small cell lung cancer patients anthological tissue RRM1,ERCC1 had significant positive correlation with chemotherapeutic effect (r =0.248,0.306,all P ＜ 0.05).Conclusion Gemcitabine has a certain clinical effect in the treatment of non-small cell lung cancer patients,and the clinical effect had significant positive correlation with the negative expression of non-small cell lung cancer patients anthological tissue RRMl,ERCC1 protein,which can act as the evaluation index for the chemotherapeutic effect.